Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P13 SC Maintenance Therapy in Moderately to Severely Active Crohn's Disease
2019-001087-30Phase 3Completed
- Sponsor
- Celltrion
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing CT-P13 SC maintenance with Placebo SC (2 arms). Primary endpoints: Clinical remission at Week 54 and Endoscopic response at Week 54. Started Jun 2019; status: completed.
02
Drugs
infliximab-dyyb
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2019-001087-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001087-30.